AGP Executive Report
Last update: 2 hours agoPharma Deal: SERB Pharmaceuticals has completed the acquisition of exclusive EU/UK/Switzerland/Liechtenstein and MENA rights to Idefirix® (imlifidase) from Hansa Biopharma, aiming to expand access for patients needing time-critical transplant support. Rett Syndrome Breakthrough: Acadia’s DAYBU® (trofinetide) has received a positive CHMP opinion in the EU for neurobehavioral symptoms of Rett syndrome in adults and children aged five-plus, with EU approval now the next step. Cancer Care Update: Merck (KEYTRUDA®) plus Padcev® has been approved in the EU for adults with resectable muscle-invasive bladder cancer who can’t take cisplatin, marking a first-in-class PD-1 inhibitor plus ADC option. Arts & Screen: Warner Bros. Discovery will bring Stan’s crime thriller “The Killings at Parrish Station” to HBO Max across the UK, Ireland, Germany, Austria, Switzerland, Liechtenstein, Luxembourg and the Netherlands. Local Culture & Tradition: Swiss nationals abroad gathered at Chur’s Federal Shooting Festival, including Liechtenstein flags on the range, highlighting how sport keeps Swiss identity alive overseas. Travel Reality Check: New border delays are hitting summer travel as the EU Entry/Exit System (EES) rolls out, with queues reported at some European airports.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
